Ajay Singh, MD
Ophthalmology · Independence, MONPI 1184807786
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $51,850 of the $65,911 with a category attached, or 78.7%. AbbVie accounts for 90.8% of it on its own, with 18 other manufacturers making up the rest. Among ophthalmology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 98 payments — averaging $672.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$60K
- Alimera Sciences, Inc.$4K
- Genentech USA, Inc.$749
- Regeneron Healthcare Solutions, Inc.$364
- Apellis Pharmaceuticals, Inc.$231
- Novartis$198
- plus $914 from 13 others
Across 10 payments — averaging $3316.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$23K
- ANI Pharmaceuticals, Inc.$10K
What the payments were for
- Speaking & faculty fees$51,85079%
- Travel & lodging$8,77213%
- Food & beverage$5,2748%
- Other$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $59,869 |
| Alimera Sciences, Inc. | 17 | $3,586 |
| Genentech USA, Inc. | 11 | $749 |
| Regeneron Healthcare Solutions, Inc. | 3 | $364 |
| Apellis Pharmaceuticals, Inc. | 3 | $231 |
| Novartis | 2 | $198 |
| Astellas Pharma US Inc | 2 | $177 |
| Mallinckrodt Hospital Products Inc. | 1 | $122 |
| Regeneron | 1 | $118 |
| Cardinal Health 200 LLC | 1 | $113 |
| ANI Pharmaceuticals, Inc. | 1 | $113 |
| The Cameron-ehlen Group, Inc. | 1 | $109 |
| Alcon | 2 | $41 |
| Coherus Oncology, Inc. | 1 | $27 |
| Eyepoint US, Inc. | 2 | $27 |
| Biogen | 1 | $22 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $17 |
| Baxter Healthcare | 1 | $15 |
| Iridex Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$59,392
- Iluvien$3,343
- EYLEA$354
- Tecnis IOL$328
- VABYSMO$260
- YUTIQ$161
- SUSVIMO$146
- EYLEA HD$128
- ACTHAR$122
- PURIFIED CORTROPHIN GEL$113
- HEALON PRO$109
- Tecnis Simplicity$109
How this compares
$65,911 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 150 | $6,428 |
| Difluprednate | 41 | $4,980 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $3,810 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 17 | $1,871 |
| Timolol Maleate | 104 | $919 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 107 | $790 |
| Atropine Sulfate | 19 | $653 |
| Brimonidine Tartrate | 28 | $562 |
| Latanoprost | 19 | $480 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 13 | $148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan | $59,869 | $3,81019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Independence
- Rohit KrishnaIndependence$57K
- Steven SilversteinKansas City$872K
- Ranjan MalhotraSaint Louis$809K
- Nancy HolekampChesterfield$768K
- Jay PeposeChesterfield$516K
- Gregg BerdySaint Louis$360K
- Joseph GiraDes Peres$174K
- Joseph TauberKansas City$174K
- Jella AnColumbia$166K
- Shachar TauberSpringfield$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.